Lisa B Nachtigall
Overview
Explore the profile of Lisa B Nachtigall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
R O L Schweizer J, Nachtigall L
Pituitary
. 2024 Jun;
27(4):317-319.
PMID: 38940858
No abstract available.
2.
Fleseriu M, Nachtigall L, Samson S, Melmed S
Expert Rev Endocrinol Metab
. 2024 Jun;
19(4):367-375.
PMID: 38842362
Introduction: Acromegaly is a rare endocrine disorder usually caused by a benign growth hormone‒secreting pituitary adenoma. Surgical adenoma resection is typically the first line of treatment, and medical therapy is...
3.
Remba-Shapiro I, Nachtigall L
Best Pract Res Clin Endocrinol Metab
. 2024 Mar;
38(4):101888.
PMID: 38443224
Acromegaly is a rare disease caused by a growth hormone excess, usually due to a secreting pituitary adenoma. Somatostatin receptor ligands (SRL) are the mainstay of medical therapy for patients...
4.
Nyanyo D, Mikamoto M, Galbiati F, Remba-Shapiro I, Bode K, Schoenfeld S, et al.
Ann Intern Med
. 2024 Feb;
177(3):315-323.
PMID: 38373302
Background: Glucocorticoids suppress inflammation. Autoimmune disease may occur after remission of Cushing's disease (CD). However, the development of autoimmune disease in this context is not well described. Objective: To determine...
5.
Vakharia J, Muhammed M, Remba-Shapiro I, Marsiglia M, Hadaway N, Chwalisz B, et al.
Eur J Endocrinol
. 2023 Aug;
189(3):309-317.
PMID: 37602514
Objective: To determine pituitary function before and after nonglucocorticoid immunosuppressive therapy (NGIT) in subjects with hypophysitis and evaluate their clinical and radiologic outcomes. Design: Retrospective, longitudinal study. Methods: We reviewed...
6.
Samson S, Nachtigall L, Fleseriu M, Jensterle M, Manning P, Elenkova A, et al.
Eur J Endocrinol
. 2022 Sep;
187(6):733-741.
PMID: 36173649
Objective: The objective of this study is to report results from the open-label extension (OLE) of the OPTIMAL trial of oral octreotide capsules (OOC) in adults with acromegaly, evaluating the...
7.
Kimball A, Dichtel L, Yuen K, Woodmansee W, Haines M, Nachtigall L, et al.
Pituitary
. 2022 Apr;
25(3):531-539.
PMID: 35476257
Purpose: To assess long-term quality of life (QoL) in patients with sustained biochemical control of acromegaly, comparing those receiving vs not receiving pharmacotherapy (primary analysis); to assess change in QoL...
8.
Hoskova K, Kayton Bryant N, Chen M, Nachtigall L, Lippincott M, Balasubramanian R, et al.
J Clin Endocrinol Metab
. 2022 Mar;
107(8):e3515-e3525.
PMID: 35323937
Context: Hyperprolactinemia suppresses gonadotropin-releasing hormone (GnRH)-induced luteinizing hormone (LH) pulses. The hypothalamic neuropeptide kisspeptin potently stimulates the secretion of GnRH. The effects of exogenous kisspeptin administration on GnRH pulse generation...
9.
Geer E, Kilgallon J, Liebert K, Kimball A, Nachtigall L
Eur J Endocrinol
. 2022 Jan;
186(3):341-349.
PMID: 35032385
Objectives: To assess the impact of virtual education programming for patients with acromegaly. Design: We conducted a mixed methods study to evaluate patient attitudes, examine if patient-centered educational forums change...
10.
Guarda F, Yu X, Shiraliyeva N, Haines M, Bradbury M, Saylor P, et al.
Pituitary
. 2021 Apr;
24(5):681-689.
PMID: 33835355
Purpose: To examine the clinical presentation and longitudinal outcome of Pituitary Apoplexy (PA) after gonadotropin-releasing hormone agonist (GnRHa) in a series of patients and compare to prior reports. Methods: A...